Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
SSR Mining Announces Voting Results From 2024 Annual and Special Meeting of Shareholders
-
Tiny Announces Annual General and Special Meeting of Shareholders
-
Pan American Silver Releases 2023 Sustainability Report
-
HRBR Stockholders: Robbins LLP Reminds HRBR Stockholders of Securities Fraud Class Action Against Harbor Diversified, Inc.
-
DOCS INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
-
Trailblazing Dragons' Den Star Named United Nations Association in Canada's 2024 Global Citizen Laureate
-
INTC Stockholders: Robbins LLP Reminds INTC Stockholders of Securities Fraud Class Action Against Intel Corporation
-
Graphic Packaging Holding Company Declares Quarterly Dividend
-
Crypto Specialist Bitwise’s First-Ever Spot Ethereum ETF Receives Key SEC Approval
-
Sailfish Reports Q1 2024 Results
-
Gesa Credit Union Announces Agreement to Acquire Security State Bank
-
EDETEK to Showcase "End-to-End Digital Data Pipeline for Clinical Trials" at AWS Healthcare and Life Sciences Meetup in Los Angeles, CA
-
Pei enters the MSCI COLCAP index
-
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
-
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
-
NextEra Energy board declares quarterly dividend
-
Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts to its Data Centers
-
American Aires Extends Global Expansion by Opening Latest International Fulfillment Center in the UK
-
Deveron Announces Dates for Q3 2024 Earnings Release
-
Aurania Announces Closing of Tranche 2 of Private Placement
-
Avenix Fzco Introduces New Expert Advisor Pivozon for Enhanced Forex Trading on EURUSD
-
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
-
Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2024 Annual Meeting
-
PARAMOUNT GLOBAL AND CHARTER COMMUNICATIONS ANNOUNCE NEW MULTI-YEAR AGREEMENT FOR DISTRIBUTION OF PARAMOUNT'S LINEAR NETWORKS, CBS OWNED-AND-OPERATED STATIONS AND DIRECT-TO-CONSUMER STREAMING SERVICES
-
NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement
-
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SILVERCORP REPORTS ADJUSTED NET INCOME OF $39.3 MILLION, $0.22 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $91.6 MILLION FOR FISCAL 2024
-
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
-
Special Olympics Florida and Orlando Health Announce Five-Year Partnership
-
Extraordinary 80+ Acre Paradise Island, Boca Grande, FL, Hits Market After 70-Years: A Once-in-a-Lifetime Opportunity for Discerning Buyers
-
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
-
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
-
Barnes & Noble Education Announces Preliminary Fiscal Year 2024 Results
-
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
-
KinderCare Learning Companies Applauds Bipartisan Effort to Support Working Families through Child Care Access
-
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
-
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
-
EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
-
Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening
-
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (m
-
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
-
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Ann
-
ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024
-
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel
-
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
-
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the
-
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting

